Trial Profile
A Phase 2 Study of Ataluren (PTC124) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Methylmalonic acidaemia
- Focus Therapeutic Use
- Sponsors PTC Therapeutics
- 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 03-Nov-2011), according to European Clinical Trials Database record.
- 16 Jan 2018 Status changed to discontinue.
- 01 Apr 2014 New trial record